Clarification regarding previous statements by the CFO

9/7/2012 2:45 AM EST

Oasmia Pharmaceutical AB
Company Announcement

Clarification regarding previous statements by the CFO

Uppsala, Sweden, 2012-09-07 08:45 CEST (GLOBE NEWSWIRE) -- 

The reason behind today’s stoppage in trade with the Oasmia share is comments
made to the Swedish News Agency Nyhetsbyrån Direkt, regarding the company
prospects for business agreements and development. 

As replies to direct questions, the CEO made the following time based
estimations: 

  -- Convinced to reach an agreement for Paclical® for a minor geographic area
     before the end of the year
  -- Paclical®-agreement for the EU possible in this calendar year.
  -- Indications that the FDA may make a decision in November concerning Paccal®
     Vet
  -- Phase I results for Doxophos® are reasonably expected before the end of the
     year
  -- It is feasible to think that a new application concerning Paccal® Vet may
     be filed with the EMA in the first half of 2013.
  -- The company must acquire capital in the autumn and a decision should be
     expected in October.

The Board of Directors emphasizes the difficulty in estimating the time when
expected events will occur. The above estimations of times are not supported by
the Board and the Board wants for this reason emphasize the following: Oasmia
is involved in ongoing negotiations for all major markets and the interest has
risen significantly in the year. The prospects for agreements are very good
both in short and long terms. It is natural for the management of a development
company to work continually with different solutions for financing and the
current situation is according to plan. 

Oasmia is sorry for the events and will from now on inform the market in
accordance with current practice. 


         Maria Lundén, Head of Public Relations, Oasmia Pharmaceutical AB.
         E-mail:   Phone: +46 (0) 18 50 54 40. www.oasmia.com
www.nasdaqomxnordic.com www.boerse-frankfurt.de